We studied adenosine diphosphate-induced platelet aggregation and the associated release of thromboxane B^ in 49 patients with subarachnoid hemorrhage in relation to angiographic vasospasm. Postoperative cerebral angiography was performed ^3 (median 1) days after surgery for an aneurysm 5-14 days after subarachnoid hemorrhage. Correspondingly, one sample from each patient was taken within 24 hours either before or after angiography. The occurrence of severe as well as diffuse, moderate, or severe angiographic vasospasm was associated with the presence of delayed cerebral ischemia (p<0.05). Patients with diffuse angiographic vasospasm had significantly higher (/?<0.05) values for thromboxane B 2 release than the others, even after adjustment by the clinical grades on admission and before surgery, the timing of surgery, the time from subarachnoid hemorrhage to angiography and blood sampling, and nimodipine therapy. Severe and diffuse angiographic vasospasm were also associated with poor outcome at 1 year (p<0.05). Our results suggest that augmented release of platelet thromboxane may be involved in the pathogenesis of vasospasm in large cerebral arteries. (Stroke 1991^2:451-455) D elayed cerebral ischemia is an important cause of mortality and morbidity after aneurysmal subarachnoid hemorrhage (SAH). Delayed ischemia may be due to vasospasm in large cerebral arteries (visualized on angiograms), and/or vasospasm in small arteries and arterioles in the pial membrane and within the brain parenchyma (not visualized on angiograms), and/or increased platelet aggregation. 1 ' 2 Thromboxane A 2 released by platelets is a potent vasoconstricting and platelet aggregating agent that might be involved in delayed ischemia. Received October 8, 1990; accepted December 17, 1990. the prevention of cerebral ischemia in patients after SAH.
D elayed cerebral ischemia is an important
cause of mortality and morbidity after aneurysmal subarachnoid hemorrhage (SAH).
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The pathogenesis of delayed ischemia after SAH is unclear. Severe, diffuse vasospasm demonstrated by angiography seems to be associated with symptoms of delayed ischemia. 1 -5 Delayed ischemia may be due to vasospasm in large cerebral arteries (visualized on angiograms), and/or vasospasm in small arteries and arterioles in the pial membrane and within the brain parenchyma (not visualized on angiograms), and/or increased platelet aggregation. 1 ' 2 Thromboxane A 2 released by platelets is a potent vasoconstricting and platelet aggregating agent that might be involved in delayed ischemia. 6 - 8 Few reports are available on the possible beneficial effect of thromboxane synthetase inhibitors on vasospasm in experimental animals 9 - 11 and on the prevention of cerebral ischemia in patients after SAH.
12
- 13 We studied adenosine diphosphate (ADP)-induced platelet aggregation and the associated release of thromboxane in relation to large cerebral arterial vasospasm seen on angiograms.
Subjects and Methods
Our study comprised 49 patients (28 men and 21 women) aged 22-64 (median 40.1) years who were admitted ^96 hours after the onset of aneurysmal SAH to the Department of Neurosurgery at the Helsinki University Central Hospital and who were studied by cerebral angiography 5-14 days after SAH. Patients who had used nonsteroidal anti-inflammatory drugs during the week before surgery were excluded from the study.
The SAH was verified by computed tomography (CT) in all patients. Each patient's clinical grade on admission and before surgery was classified according to Hunt and Hess 14 ( Table 1 ). The occurrence of intracerebral and intraventricular bleeding, the location of the ruptured aneurysm, previous hypertension, and the timing of surgery are also shown in Table 1 . The median time from SAH (day 0) to surgery in all 49 patients was 7.0 (range 2-13) days, and the timing of surgery in 37 patients was randomized in another study 15 (Table 1) . ; 12 patients were not randomized because they 1) were admitted too late for randomization (n=7), 2) had deteriorated after admission from grades I-III to FV-V prior to possible randomization (n=3), or 3) had an aneurysm in vertebrobasilar region (n=2).
Twenty-five patients received nimodipine and 20 received placebo in a double-blind fashion. 16 Four patients received neither nimodipine nor placebo because they were admitted before the beginning of that study. The interval from the onset of SAH to the start of intravenous nimodipine or placebo averaged 2.2 (range 0.7-5.0) days. The dose of intravenous nimodipine or placebo was 0.5 Aig/kg/min. The intravenous therapy was maintained until 7-10 days after the onset of SAH. Thereafter, oral administration (60 mg tablets every 4 hours) was continued for up to 21 days after the SAH. Patients routinely received 4 mg i.m. betamethasone every 6 hours starting the day before surgery; betamethasone administration continued until 6 days after surgery in diminishing doses.
Severe hypertension was treated with vasodilators. Headache was treated with narcotic analgesics and sedatives.
Both the severity and the distribution of vasospasm were noted on the postoperative angiogram. Vasospasm was graded as severe if the lumen was narrowed to ^50% of its original diameter (measured from a preoperative angiogram done shortly after admission), moderate for 30-50% narrowing, and none or mild for <30% compromise of the lumen. Moderate or severe vasospasm was considered local if it involved only one or a portion of one major vascular distribution and diffuse if it involved more than one vascular distribution. Postoperative angiography was performed ^3 days after surgery (19 on day 0, 23 on day 1, six on day 2, and one on day 3).
Fasting blood samples were collected from 30 patients in the morning before the postoperative angiogram and from the remaining 19 patients (in whom angiography was performed within a few hours after surgery) in the morning following surgery and angiography. To study the release of thromboxane A 2 from platelets (measured as the concentration of the stable metabolite thromboxane Bj [TXBJ), we applied the method of ADP-induced platelet aggregation described in detail elsewhere. 7 We used 8 pM ADP based on our earlier observations. 78 All samples showed secondary-phase (irreversible) platelet aggregation. The thromboxane formation capacity in 1 1 blood was calculated as the product of TXB 2 release and the platelet count. Platelet studies were performed by one laboratory technician, and angiograms were analyzed by one of us who was blinded to the case histories of the patients.
Deterioration of clinical status was recorded at daily clinical examinations. Delayed ischemia with fixed neurological deficit was regarded as the gradual development of totally or partially irreversible neurological signs not due to intracerebral hematoma, rebleeding, hydrocephalus, or other verified causes. These causes of deterioration were excluded by CT, routine postoperative angiography, laboratory investigations, or autopsy. Outcome was assessed at 1 year according to the Glasgow Outcome Scale. 17 Categorical variables were compared using the x 2 test or Fisher's exact two-tailed test. The TXBz concentrations were subjected to logarithmic transformation because of a skewed distribution. TXB2 release and thromboxane formation capacity are expressed as median ± standard error of the median (SE), and time after SAH is expressed as median with ranges. Other interval-scale values are expressed as mean±standard error of the mean (SEM). The association of preoperative clinical grade, timing of surgery, time from SAH to angiography, and outcome with angiographic vasospasm were analyzed by using the Mann-Whitney U test or Kruskal-Wallis one-way analysis of variance (ANOVA) with multiple pairwise comparisons. The dependent variables of platelet function were analyzed by Student's t test or ANOVA with multiple pairwise comparisons us- ing Dunnett's method (patients without angiographic vasospasm being the control group). Possible confounding effects of other variables (sex, age, hypertension, clinical grade, timing of surgery, time from SAH to angiography and blood sampling, or treatment with nimodipine) on platelet function were tested by two-way ANOVA or analysis of covariance.
Results Twenty-two patients (44.9%) had moderate or severe vasospasm, and 19 patients (38.8%) had diffuse vasospasm on the postoperative angiogram (Table 2). Sex, age, hypertension, clinical grade on admission, the presence of intraventricular or intracerebral hemorrhage, and location of the ruptured aneurysm had no significant association with the severity or distribution of vasospasm (data not shown).
Patients with severe or diffuse vasospasm were operated on in a poorer clinical state and later after SAH than the others ( Table 2 ). The time from SAH to surgery and angiography were associated with the severity and distribution of vasospasm because angiography in nine of the 13 patients with severe vasospasm was performed 7-10 days after SAH. Patients receiving nimodipine treatment had moderate or severe as well as diffuse vasospasm less often than the others, but the difference was not significant ( Table 2) .
Ten of 48 patients (21%) deteriorated due to delayed ischemia with fixed neurological deficit. One patient deteriorated shortly after admission due to a space-occupying intracerebral hematoma, and thereafter no determination of possible cerebral ischemia could be made because of a poor clinical state. Severe as well as diffuse vasospasm was significantly associated (/><0.05) with delayed ischemia. Of 10 patients with delayed ischemia six had severe vasospasm and seven had diffuse vasospasm. Five patients had rebleeding, and rebleeding was not associated with the severity or distribution of vasospasm.
Platelet aggregation and platelet count did not differ significantly by the severity or distribution of vasospasm, although platelet count tended to increase with the severity of vasospasm (Table 3) .
The TXBj release and the thromboxane formation capacity were significantly associated with angiographic vasospasm (Table 3) . Patients with severe vasospasm had significantly higher values for TXBr elease (/?<0.05) and thromboxane formation capacity (/?<0.01) than those without vasospasm. The significant differences disappeared after adjustment by preoperative clinical grade, days to surgery, and days to angiography. Patients with diffuse vasospasm had significantly higher values for TXB2 release (p<0.01) and thromboxane formation capacity (p<0.01) than the others. The differences remained significant (p<0.05) for both thromboxane variables after adjustment by preoperative clinical grade, nimodipine therapy, days to surgery, and days to angiography. Days to surgery and nimodipine therapy were not significantly associated with TXB2 release, but patients with nimodipine treatment had lower values for TXB2 release than those without nimodipine therapy (2,249+551 and 2,691+796 fmol/10 
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Data are mean±SEM for platelet variables and median ±SE for thromboxane variables. *p<0.05 different from no-mild vasospasm for thromboxane release andp <0.01 for thromboxane formation capacity without adjustment by preoperative clinical grade, days to surgery, and days to angiography, no significant differences after adjustment.
1p<0.0l different from no-local vasospasm for thromboxane variables without adjustment by preoperative clinical grade, days to surgery, and days to angiography; p<0.05 after adjustment.
Outcome was significantly associated with angjographic vasospasm. Patients with severe vasospasm had significantly (p<0.05) poorer outcome than those with no or mild vasospasm. Seven of the 13 patients (54%) with severe vasospasm had moderate or severe disability compared with four of the 27 patients (15%) with mild or no vasospasm. Diffuse vasospasm was also associated with significantly (/?<0.05) poorer outcome than no or local vasospasm. Eight of the 19 patients (42%) with diffuse angiographic vasospasm had moderate or severe disability, and four of the other 30 patients (13%) had corresponding disability. No patient was in a vegetative state, and two patients who died had local, mild vasospasm. One patient died of delayed ischemia and another of trauma after discharge from the hospital.
Discussion
Severe angiographic vasospasm, which is usually also diffuse, has been shown to be associated with delayed cerebral ischemia and poor outcome, although not all patients with severe vasospasm have symptoms of ischemia, most likely because of a sufficient collateral circulation. 1 -5 In our study, the severity and distribution of angiographic vasospasm as well as the occurrence of delayed ischemia corresponded to those in previous studies. 1 -518 The cause of vasospasm seems to be multifactorial, and there is increasing evidence that platelets have an important role. 1 -78 Platelets may adhere to the damaged endothelium and subendothelium after SAH and release vasoactive substances that promote platelet aggregation and vasoconstriction. 1 -6 Recently, Yamazaki et al 19 showed in a rabbit model that injection of ADP into the cerebral arteries caused severe vasoconstriction and concomitant vascular injury in middle-sized and large arteries and increased the blood levels of TXB2 without preinjection endothelial damage. These changes were not seen if blood in the cerebral circulation was replaced by physiological saline before the ADP injection. These researchers concluded that platelet thromboxane A 2 may be important in the pathogenesis of vasospasm. 19 We have previously shown that platelet TXB2 release was increased in the presence of delayed ischemia and after surgery, whereas it was decreased ^3 days after SAH and during intravenous nimodipine therapy in humans.
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We observed elevated values for TXB2 release in patients with severe and/or diffuse angiographic vasospasm after aneurysmal SAH. Because angiographic vasospasm is a time-dependent phenomenon, we included in this study only patients with angiography performed 5-14 days after SAH, and thereafter we statistically excluded the confounding effects of the time from SAH to angiography and blood sampling on the association between vasospasm and TXB2 release. The association of diffuse vasospasm with TXB2 release remained significant after adjustment by these and other confounding factors. Although we had no samples from healthy controls in this study, we can approximately compare the results of this study with those of our previous study, in which we had healthy controls and the methodology was identical. 7 In that study, the median ±SE values for TXB2 release and thromboxane formation capacity of the controls were 2,285±464 fmol/10 7 platelets and 45±13 nmol/1, respectively. 7 These values are comparable to those of patients without vasospasm, but patients with severe or diffuse vasospasm have values significantly (/><0.05) greater than the controls.
The role of thromboxane in ischemia is unknown. Thromboxane might cause vasospasm in large and/or small arteries, or increase platelet aggregation, or be an epiphenomenon. Although this study showed an association between platelet TXB2 release and large-vessel vasospasm, it does not rule out the effects of thromboxane on the other above-mentioned mechanisms. This study also does not indicate a causal relationship between thromboxane and vasospasm after SAH.
Orally administered nimodipine has been shown to decrease the incidence and severity of delayed ischemia without reversing angiographic vasospasm. 1820 Intravenous nimodipine may decrease the chance of ischemia by decreasing platelet thromboxane release. 8 It is unknown whether the intravenous administration of nimodipine decreases the severity and distribution of angiographic vasospasm if started soon after SAH since it is well known that the reversal of prolonged vasospasm is difficult or perhaps impossible. 12 
